|
An open, multicentric, phase IV clinical trial to assess the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals’ combined diphtheria-tetanus-acellular pertussis vaccine (Infanrix™) administered to healthy infants at 2, 4 and 6 months of age. |
Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed |
101197 (DTPa -127) |
|
Acellular pertussis; Diphtheria; Tetanus |
Phase 4 |
|
|
|
|
An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies. |
September 2013 |